| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 433.71% | £373,595.52 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 339.48% | £307,635.46 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 237.51% | £236,255.31 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 66.11% | £116,275.23 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 54.17% | £107,918.40 |
| Lord Mance |
|
Stryker / NYQ:SYK | 34.73% | £94,309.09 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 4.16% | £72,910.25 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | 2.04% | £71,428.05 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -7.70% | £64,609.51 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -35.85% | £44,902.28 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -78.52% | £15,036.25 |